PPARG and early-onset autosomal dominant Alzheimer disease: It would, however, be interesting to further explore if treatment with GW9662 and subsequently PPARγ antagonism has global neurotoxicity as suggested by studies in other neurodegenerative diseases including Huntington's disease (Quintanilla et al., 2008) and Alzheimer's disease (Du et al., 2009).